Janux Therapeutics, Inc. 8-K

What Happened

• Janux Therapeutics (NASDAQ: JANX) filed an 8-K (Item 5.02) on April 28, 2026 announcing that director Eric Dobmeier resigned his Class III seat and was immediately reappointed as a Class II director. The change was made to rebalance the three classes of directors on the company's board.

Key Details

• Date: April 28, 2026 (effective immediately).
• Director: Eric Dobmeier moved from Class III (term previously expiring at the 2027 Annual Meeting) to Class II (term now expiring at the 2026 Annual Meeting).
• Continuity: The resignation and reappointment were purely procedural; Dobmeier’s board service is treated as uninterrupted for all other purposes, including vesting/settlement of outstanding equity awards and compensation.
• Committee role: Mr. Dobmeier will continue serving on the Board’s Compensation Committee.

Why It Matters

• This is a governance adjustment, not an addition or departure of a director: investors should note there is no change to board membership or director compensation/equity treatment. The change affects the timing of the director classes and upcoming director election cycles (Class II seats up at the 2026 annual meeting). Good governance practices like balanced board classes can influence investor confidence but do not directly change company operations or financial results.